Literature DB >> 28357563

The association of psychopathology with concurrent level of functioning and subjective well-being in persons with schizophrenia spectrum disorders.

Lisa Hochstrasser1, Stefan Borgwardt2, Martin Lambert3, Benno G Schimmelmann4,5, Undine E Lang2, Rolf-Dieter Stieglitz2,6, Christian G Huber2,3.   

Abstract

The objective is to investigate the relationship between psychopathology measured by the positive and negative syndrome scale (PANSS) and concurrent global assessment of functioning (GAF) and subjective well-being under neuroleptics (SWN) in patients with schizophrenia spectrum disorder (SSD) regarding severity of illness and disease phase. We analyzed a sample of 202 SSD patients consisting of first episode psychosis (FEP) and multiple episode psychosis (MEP) patients followed up to 12 months using linear mixed models. All PANSS syndromes except excitement were associated with GAF scores (positive syndrome: p < 0.001, d = 1.21; negative syndrome: p = 0.029, d = 0.015; disorganized syndrome: p < 0.001, d = 0.37; anxiety/depression syndrome: p < 0.001, d = 0.49), and positive symptoms had an increasing impact on global functioning with higher severity of illness (mildly ill: p = 0.039, d = 0.22; moderately ill: p < 0.001, d = 0.28; severely ill: p < 0.001, d = 0.69). SWN was associated with positive (p = 0.002, d = 0.22) and anxiety/depression (p < 0.001, d = 0.38) syndromes. Subgroup analyses showed differing patterns depending on illness severity and phase. Over all our results show different patterns of associations of psychopathology and concurrent functioning and subjective well-being. These findings contribute knowledge on the possible role of specific psychopathological syndromes for the functioning and well-being of our patients and may enable tailored treatments depending on severity and phase of illness.

Entities:  

Keywords:  First episode psychosis; Location index; Multiple episode psychosis; PANSS; Vocation index

Mesh:

Year:  2017        PMID: 28357563     DOI: 10.1007/s00406-017-0780-3

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  27 in total

1.  Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial).

Authors:  Martin Lambert; Thomas Bock; Daniel Schöttle; Dietmar Golks; Klara Meister; Liz Rietschel; Alexandra Bussopulos; Marietta Frieling; Michael Schödlbauer; Marc Burlon; Christian G Huber; Gunda Ohm; Manoshi Pakrasi; Michael Sadre Chirazi-Stark; Dieter Naber; Benno G Schimmelmann
Journal:  J Clin Psychiatry       Date:  2010-03-23       Impact factor: 4.384

2.  What does the PANSS mean?

Authors:  Stefan Leucht; John M Kane; Werner Kissling; Johannes Hamann; Eva Etschel; Rolf R Engel
Journal:  Schizophr Res       Date:  2005-06-27       Impact factor: 4.939

3.  Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling.

Authors:  P-M Llorca; O Blanc; L Samalin; M Bosia; R Cavallaro
Journal:  Eur Psychiatry       Date:  2011-06-30       Impact factor: 5.361

4.  What are the PANSS items most related with global improvements in patients with schizophrenia? Toward a reduced version of the PANSS.

Authors:  Bruno Bertolucci Ortiz; Ary Gadelha; Cinthia Hiroko Higuchi; José Cássio do Nascimento Pitta; Simão Kagan; Mariana Rauwey Vong; Cristiano Noto; Jaime Eduardo Cecílio Hallak; Rodrigo Affonseca Bressan
Journal:  Schizophr Res       Date:  2014-07-05       Impact factor: 4.939

5.  Examination of the Positive and Negative Syndrome Scale factor structure and longitudinal relationships with functioning in early psychosis.

Authors:  Michael W Best; Michael Grossman; L Kola Oyewumi; Christopher R Bowie
Journal:  Early Interv Psychiatry       Date:  2014-10-02       Impact factor: 2.732

6.  A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF).

Authors:  S H Jones; G Thornicroft; M Coffey; G Dunn
Journal:  Br J Psychiatry       Date:  1995-05       Impact factor: 9.319

7.  The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials.

Authors:  J M Davis; N Chen
Journal:  J Clin Psychiatry       Date:  2001-10       Impact factor: 4.384

8.  Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P).

Authors:  J Ventura; R P Liberman; M F Green; A Shaner; J Mintz
Journal:  Psychiatry Res       Date:  1998-06-15       Impact factor: 3.222

9.  Equipercentile linking of scales measuring functioning and symptoms: examining the GAF, SOFAS, CGI-S, and PANSS.

Authors:  Myrto T Samara; Rolf R Engel; Aurelie Millier; Julia Kandenwein; Mondher Toumi; Stefan Leucht
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-20       Impact factor: 4.600

10.  Psychopathological dimensions and lack of insight in schizophrenia.

Authors:  M J Cuesta; V Peralta; A Zarzuela
Journal:  Psychol Rep       Date:  1998-12
View more
  1 in total

1.  Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis.

Authors:  Lisa Hochstrasser; Erich Studerus; Anita Riecher-Rössler; Benno G Schimmelmann; Martin Lambert; Undine E Lang; Stefan Borgwardt; Rolf-Dieter Stieglitz; Christian G Huber
Journal:  Sci Rep       Date:  2022-04-22       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.